For over 20 years Bill has been involved in the development and application of pharmacometric methodology for enhancing drug treatment, development and regulation. His current interests include the use of Bayesian modeling and simulation to optimize decision-making in clinical drug development and treatment. He plans to make Bayesian modeling and simulation methods more accessible via training programs and development of software tools.
Rena J. Eudy, William R. Gillespie, Matthew M. Riggs, Marc R. Gastonguay. Linking a Mechanistic Model of Bone Mineral Density to a Time-To-Event Model of Fracture. ACoP 6. October 2015.
Klaus Romero, Vikram Sinha, Sandra Allerheiligen, Meindert Danhof, Jose Pinheiro, Naomi Kruhlak, Yaning Wang, Sue-Jane Wang, John-Michael Sauer, J. F. Marier, Brian Corrigan, James Rogers, H. J. Lambers Heerspink, Tawanda Gumbo, Peter Vis, Paul Watkins, Tina Morrison, William Gillespie, Mark Forrest Gordon, Diane Stephenson, Debra Hanna, Marc Pfister, Richard Lalonde, Thomas Colatsky. Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. Journal of Pharmacokinetics and Pharmacodynamics
December 2014, Volume 41, Issue 6, pp 545-552.
M. M. Riggs, L. J. Seman, A. Staab, T. R. MacGregor, W. Gillespie, M. R. Gastonguay, H. J. Woerle, and S. Macha. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (sglt2) inhibitor, in patients with type 2 diabetes. Br J Clin Pharmacol, Jun 2014.
Daniel G. Polhamus, Ph.D., James A. Rogers, Ph.D., William R. Gillespie, Ph.D., Jonathan French, Sc.D. Clinical Dementia Rating Modeling and Simulation: Joint progression of CDR and biomarkers in the ADNI cohort. AAIC 2013.
Jorge Luiz Gross, James Rogers, Daniel Polhamus, William Gillespie, Christian Friedrich, Yan Gong, Brigitta Ursula Monz, Sanjay Patel, Alexander Staab, Silke Retlich. A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. BMJ Open. 5 March 2013.
Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2013 Jan;109(1):77-85.
Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, Stephenson D, Gastonguay MR, Corrigan B. Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis. J Pharmacokinet Pharmacodyn. October 2012, Volume 39, Issue 5, pp 479-498.
Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2012 Sep 28.
James Rogers, Peter Lockwood, Dan Polhamus, Yves Brault, Anne Desmet, Kaori Ito, Klaus Romero, Ruolun Qiu, Bill Gillespie, Brian Corrigan, Marc Gastonguay. Model-based Analysis to Support Strategic Decision Making: A Case Study from the Development of a 5HT6 Antagonist for the Treatment of Alzheimer’s Disease.
Jorge L. Gross, James Rogers, Dan Polhamus, William Gillespie, Sanjay Patel, Christian Friedrich, Yan Gong, Brigitta Monz, Alexander Staab, Silke Retlich. Novel Model-based Meta-Analysis to Estimate comparative Efficacies of 2 Drugs: an Example Using the DPP-4 inhibitors Linagliptin and Sitagliptin in Type 2 Diabetes Mellitus. American Diabetes Association 72nd Scientific Sessions (2012).
James Rogers, Dan Polhamus, William Gillespie, Christian Friedrich, Alexander Staab, and Silke Retlich. Model-based Meta-analysis Comparison of the Effects of Linagliptin and Sitagliptin on HbA1c Levels in Patients with Type 2 Diabetes Mellitus. PAGE 21 (2012).
Dan Polhamus, Jim Rogers, Bill Gillespie, Jonathan French, and Marc Gastonguay. From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer’s Disease. PAGE 21 (2012).
Elodie L. Plan, Kyle T. Baron, Marc R. Gastonguay, Jonathan L. French, William R. Gillespie, and Matthew M. Riggs. Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension. PAGE 21 (2012) Abstr 2592.
Rogers J, Polhamus D, Ito K, Qiu R, Gillespie B, Corrigan B. The Value of Evidence Synthesis: Model-based Meta-analysis Based on the CAMD Database, the ADNI AD Cohort Data, and Literature Meta-data. 2012.
Rogers JA, Ito K, Gillespie WR, Corrigan BW, Gastonguay MR. A Longitudinal Dose-response Model for the Progression of Alzheimers Disease, Based on a Combination of Summary-level and Patient-level Data. Presented at Fourth Annual Bayesian Biostatistics Conference, Houston, TX, Jan 26–28, 2011.
Riggs MM, Gillespie WR, Gastonguay MR, Peterson MC. Extension of a Multiscale Model of Calcium Homeostasis and Bone Remodeling to Include the Progressive Effects of Estrogen Loss During Menopause Transition. Presented at National Institute of General Medical Sciences Quantitative Systems Pharmacology Workshop II. Bethesda, MD; September 9, 2010.
Romero K, Corrigan B, Tornoe CW, Gobburu JV, Danhof M, Gillespie WR, Gastonguay MR, Meibohm B, Derendorf H. Pharmacometrics as a discipline is entering the “industrialization” phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol. 2010 Sep;50(9 Suppl):9S-19S.
Gastonguay MR, Gillespie WR, Bauer RJ. Comparison of MCMC simulation results using NONMEM 7 or WinBUGS with BUGSModelLibrary. PAGE 2010.
Nathanael Dirks, Marc R. Gastonguay, William R. Gillespie, William Knebel, Matthew M. Riggs, John C. Panetta, and Bernd Meibohm. Comparative Performance of Bayesian Markov Chain Monte Carlo and Maximum Likelihood Population Estimation Methods when Applied to Nonlinear Pharmacokinetics of Monoclonal Antibodies. Presented at ASCPT 111th Annual Meeting, March 17-20, 2010
James A. Rogers, Matthew M. Riggs, Monte Cofﬁner, William R. Gillespie, Robert Burford, Francis Vanderbist, Sophie De Niet, Marc R. Gastonguay. Clinical Trial Simulation to Compare Adaptive and Fixed Designs for a Phase 3 Clinical Trial of Nacystelyn® (L-Lysine-N-acetyl-L-cysteinate) for Cystic Fibrosis. ACOP 2009.
William R. Gillespie, James A. Rogers, Kaori Ito, Marc R. Gastonguay. Population Dose-Response Model for ADAS-cog Scores in Patients with Alzheimers Disease by Meta-Analysis of a Mixture of Summary and Individual Data.
Gillespie B, Rogers JA, Ito K, Gastonguay MR. Population Dose-Response Model for ADAS-cog Scores in Patients with Alzheimer’s Disease by Meta-Analysis of a Mixture of Summary and Individual Data. ASCPT 110th Annual Meeting, March 18-21, 2009.
Gillespie B, Gastonguay MR. Prototype Model Library for Bayesian Pharmacokinetic/Pharmacodynamic (PKPD) Modeling in Winbugs.
Riggs MM, Bergsma TT, Gillespie WR, Gastonguay MR, Sprenger KJ. Use of Rpad, an Open-Source, Interactive, Web-Based Analysis Program, for Visualization During Model-Based Drug Development of Adipiplon, a GABAA Receptor Partial Agonist Under Investigation for the Treatment of Insomnia. American Conference on Pharmacometrics, 2008.
Knebel W, Bergsma T, Fisher J, Georgalis G, Gibiansky L, Gillespie WR, Riggs MM, and Gastonguay MR. Facilitating the Pharmacometrics Work-Flow with the MItools R Package. American Conference on Pharmacometrics, 2008.
Gillespie WR, Gastonguay MR, Knebel W, Georgalis G. Open Source Software Tools for Parallel Computation of Multiple MCMC Chains with WinBUGS. American Conference on Pharmacometrics, 2008.
W.R. Gillespie, M.R. Gastonguay, W. Knebel. Bayesian Approaches to Mixed Effects Models for Ordered Categorical Data. AAPS Annual Meeting, San Diego, November 2007.